Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedFeb 10, 2026
DataAggregated Company Financials
Companies5
  • 7D-6.0%
  • 3M-1.9%
  • 1Y9.9%
  • YTD-4.6%

Over the last 7 days, the Biotech industry has dropped 6.0%, driven by Genmab declining 7.6%. In the past year, the industry has gained 9.9%. In the next few years, earnings are forecast to decline by 6.5% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 10 Feb 2026DKK 163.7bDKK 40.2bDKK 18.8b6.1x8.7x4.1x
Thu, 08 Jan 2026DKK 179.5bDKK 40.7bDKK 19.0b6.4x9.4x4.4x
Sat, 06 Dec 2025DKK 176.4bDKK 40.8bDKK 19.1b6.1x9.3x4.3x
Mon, 03 Nov 2025DKK 168.5bDKK 39.2bDKK 16.9b12.7x10x4.3x
Wed, 01 Oct 2025DKK 169.6bDKK 38.8bDKK 16.7b12.6x10.1x4.4x
Fri, 29 Aug 2025DKK 149.3bDKK 38.9bDKK 16.8b11.3x8.9x3.8x
Sun, 27 Jul 2025DKK 137.1bDKK 26.9bDKK 7.3b13.2x18.8x5.1x
Tue, 24 Jun 2025DKK 123.3bDKK 27.1bDKK 7.4b10.7x16.7x4.5x
Thu, 22 May 2025DKK 129.4bDKK 28.0bDKK 7.9b10.5x16.4x4.6x
Sat, 19 Apr 2025DKK 124.4bDKK 27.3bDKK 7.7b11.2x16.2x4.6x
Mon, 17 Mar 2025DKK 144.9bDKK 27.3bDKK 7.7b12.3x18.9x5.3x
Wed, 12 Feb 2025DKK 152.2bDKK 26.0bDKK 4.7b15.3x32.4x5.8x
Fri, 10 Jan 2025DKK 170.6bDKK 26.0bDKK 4.7b18x36.3x6.6x
Sun, 08 Dec 2024DKK 173.1bDKK 26.0bDKK 4.7b17.8x36.9x6.6x
Tue, 05 Nov 2024DKK 176.2bDKK 25.5bDKK 5.5b20.8x32.2x6.9x
Thu, 03 Oct 2024DKK 178.4bDKK 25.5bDKK 5.5b21.6x32.6x7x
Sat, 31 Aug 2024DKK 203.5bDKK 25.5bDKK 5.5b25.4x37.2x8x
Mon, 29 Jul 2024DKK 201.2bDKK 24.8bDKK 5.6b18.4x35.7x8.1x
Wed, 26 Jun 2024DKK 182.9bDKK 24.8bDKK 5.6b16.6x32.5x7.4x
Fri, 24 May 2024DKK 182.8bDKK 24.8bDKK 5.6b19x32.5x7.4x
Sun, 21 Apr 2024DKK 178.7bDKK 23.9bDKK 5.0b18.9x35.5x7.5x
Tue, 19 Mar 2024DKK 189.6bDKK 23.9bDKK 5.0b19.5x37.7x7.9x
Thu, 15 Feb 2024DKK 165.3bDKK 23.3bDKK 4.2b22.7x39.7x7.1x
Sat, 13 Jan 2024DKK 182.0bDKK 23.3bDKK 4.2b25.5x43.7x7.8x
Mon, 11 Dec 2023DKK 182.3bDKK 23.3bDKK 4.2b26.3x43.8x7.8x
Wed, 08 Nov 2023DKK 160.7bDKK 22.0bDKK 4.7b18.9x33.9x7.3x
Fri, 06 Oct 2023DKK 189.6bDKK 22.0bDKK 4.7b22.4x40x8.6x
Sun, 03 Sep 2023DKK 200.9bDKK 22.0bDKK 4.7b23.8x42.5x9.1x
Tue, 01 Aug 2023DKK 207.5bDKK 19.5bDKK 4.4b36x47.1x10.6x
Thu, 29 Jun 2023DKK 196.5bDKK 19.5bDKK 4.4b41x44.6x10.1x
Sat, 27 May 2023DKK 214.9bDKK 19.5bDKK 4.4b42.1x48.8x11x
Mon, 24 Apr 2023DKK 210.8bDKK 17.9bDKK 3.5b32.9x59.6x11.8x
Wed, 22 Mar 2023DKK 192.6bDKK 17.9bDKK 3.5b30.1x54.3x10.8x
Fri, 17 Feb 2023DKK 208.1bDKK 14.7bDKK 3.3b31.8x63.6x14.1x
Price to Earnings Ratio

63.6x


Total Market Cap: DKK 208.1bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 31.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 8.7x which is lower than its 3-year average PE of 31.8x.
  • The 3-year average PS ratio of 7.1x is higher than the industry's current PS ratio of 4.1x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 79% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-6.39%
Healthcare-14.66%
Biotech-6.03%
Biotech-6.03%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BIOPOR BioPortoDKK 0.980.1%
+DKK 495.1k		-35.9%PS13.3x

Latest News

BIOPOR
DKK 0.98
BioPorto
7D
0.1%
1Y
-35.9%
BAVA
DKK 192.55
Bavarian Nordic
7D
-2.6%
1Y
10.9%
ZEAL
DKK 415.90
Zealand Pharma
7D
-2.7%
1Y
-41.9%
GMAB
DKK 1,931.50
Genmab
7D
-7.6%
1Y
41.2%

GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook

Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.
STRAP
DKK 572.00
Strategic Partners
7D
-5.0%
1Y
-26.8%